Jesus San-Miguel
Overview
Explore the profile of Jesus San-Miguel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
104
Citations
6594
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shi Q, Paiva B, Pederson L, Dimier N, Talpes E, Prior T, et al.
J Clin Oncol
. 2025 Feb;
:JCO2402020.
PMID: 39938021
Purpose: Newly approved drugs and combinations treating multiple myeloma (MM) have resulted in substantial improvements in patients' survival. To deliver rapid access to newer therapies, an earlier end point to...
2.
Richardson P, Perrot A, San-Miguel J, Beksac M, Spicka I, Leleu X, et al.
Future Oncol
. 2025 Jan;
21(6):653-663.
PMID: 39851267
No abstract available.
3.
Ocio E, Perrot A, Moreau P, Mateos M, Bringhen S, Martinez-Lopez J, et al.
Hemasphere
. 2024 Nov;
8(11):e70041.
PMID: 39507853
No abstract available.
4.
Lakhwani S, Mateos M, Martinez-Lopez J, Paiva B, Rosinol Dachs L, Martinez R, et al.
Ann Hematol
. 2024 Oct;
103(12):5651-5661.
PMID: 39438321
Information on the prognostic value of immunoparesis (IP) recovery in multiple myeloma (MM) patients has been only generated in some observational and retrospective studies. We have evaluated the prognostic impact...
5.
Lasa M, Notarfranchi L, Agullo C, Gonzalez C, Castro S, Perez J, et al.
J Clin Oncol
. 2024 Oct;
43(2):125-132.
PMID: 39353166
JCO In multiple myeloma (MM), measurable residual disease (MRD) is assessed in bone marrow (BM). However, less invasive evaluation of peripheral residual disease (PRD) in blood could be advantageous and...
6.
Zabaleta A, Blanco L, Kim P, Bisht K, Wang H, van de Velde H, et al.
Br J Haematol
. 2024 Sep;
205(6):2262-2267.
PMID: 39308023
There is accumulating evidence of BCMA and GPRC5D loss after treatment with T-cell redirecting therapies in patients with relapsed/refractory multiple myeloma (RRMM). While complete CD38 loss is not observed upon...
7.
San-Miguel J, Dhakal B, Patel N, Schecter J, Lendvai N, Einsele H
Future Oncol
. 2024 Aug;
20(33):2509-2520.
PMID: 39110421
What Is This Summary About?: This is a summary of a called CARTITUDE-4. This trial compared the anti-cancer therapy ciltacabtagene autoleucel (or cilta-cel) with standard therapies in people who have...
8.
Palacios-Berraquero M, Rodriguez-Marquez P, Calleja-Cervantes M, Berastegui N, Zabaleta A, Burgos L, et al.
Blood Adv
. 2024 Jul;
8(21):5479-5492.
PMID: 39058976
Hematologic toxicity is a common side effect of chimeric antigen receptor T-cell (CAR-T) therapies, being particularly severe among patients with relapsed or refractory multiple myeloma (MM). In this study, we...
9.
Raje N, Cohen A, Patel K, van de Donk N, Richter J, San-Miguel J
Clin Lymphoma Myeloma Leuk
. 2024 Apr;
24(6):350-357.
PMID: 38627181
Immunotherapeutic strategies, specifically T-cell-redirected therapies, have been transformative in the context of multiple myeloma (MM). With the approval of two chimeric antigen receptor T-cell (CAR-T) drug products and three bispecific...
10.
Lakhwani S, Rosinol L, Puig N, Pico-Picos M, Medina-Gonzalez L, Martinez-Lopez J, et al.
Haematologica
. 2023 Nov;
109(6):1909-1917.
PMID: 38031761
Immunoparesis (IP) in multiple myeloma (MM) patients can be measured by classic assessment of immunoglobulin (Ig) levels or by analysis of the uninvolved heavy/light chain pair of the same immunoglobulin...